Inlyta (axitinib) is a small molecule pharmaceutical. Axitinib was first approved as Inlyta on 2012-01-27. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 2. In addition, it is known to target serine/threonine-protein kinase PLK4. Inlyta's patents are valid until 2036-11-05 (FDA).
|Indication||renal cell carcinoma|
|Drug Class||Tyrosine kinase inhibitors|